The Desmoid Tumor Research Foundation

March 2019

Single institution experience of split course radiotherapy in patients with desmoid tumors

Author Information

Luo J(1)(2), Jin K(1)(2), Qian S(1)(2), Ma X(1)(2), Pan Z(1)(2), Yao W(1)(2), Zhang Z(1)(2), Guo X(1)(2), Yu X(1)(2).

(1)Dept of Radiation Oncology, Fudan Univ Shanghai Cancer Center, Shanghai 200032, China. (2)Dept of Oncology, Shanghai Medical College, Fudan Univ, Shanghai 200032, China.

Publication

Onco Targets Ther

Summary

This study aimed to assess the feasibility of split course radiotherapy (SCRT) and reports long-term outcomes in patients with desmoid tumors (DT). Between 2001 and 2004, 31 patients with recurrent (n=19) or primary large desmoid fibromatosis (≥10 cm) (n=12) who were treated with SCRT were retrospectively analyzed. All patients were treated with two phases of radiotherapy with a median interval time of 99 days (range: 81-122 days) and a median total dose of 6,399 cGy (range: 5,013-7,039 cGy). The progression free survival (PFS) rate at 3 and 5 years for the whole population was 90% and 71.3%, respectively. PFS for patients with split course of <100 days or ≥100 days interval was 100% vs 78.6% at 3 years, and 80.4% vs 62.9% at 5 years, respectively (P=0.189). In multivariate analysis, the radiotherapy (RT) interval time was an independent prognostic factor for PFS (≥100 days vs <100 days, HR 11.544, 95% CI 1.034-128.878, P=0.047). Radiation-related acute complications occurred in nine (29%) patients after RT, and RT-related long-term complications occurred in three (9.7%) patients. SCRT with an appropriate treatment interval (<100 days) is well tolerated by DT patients with favorable long-term outcomes.

View Abstract